cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.23939244.v1
title: Data

description: The data is used for a TVP-SV-VAR analysis.
DOI: 10.6084/m9.figshare.23939280
title: Supplementary Material for: Systematic review and meta-analysis: Association between preoperative ustekinumab and surgical complications in Crohn's disease patients

description: Introduction: The impact of ustekinumab (UST) therapy on surgical complications in patients with Crohn's disease (CD) remains controversial. The aim of this meta-analysis is to explore the link between these two. Methods: Databases (PubMed, Web of Science, Cochrane, and Springer Link) were searched until April 2022. Studies of CD patients who received UST and no UST prior to surgery (including no biological therapy, anti-TNF-α agent, and VDZ) were included. Primary outcomes included overall complications, infectious complications, and non-infectious complications. Results: Nine studies totaling 3,225 CD patients were enrolled; 332 patients received UST treatment. There was no evidence of difference in the overall complications (OR=0.84, p=0.37, 95%CI=[0.57-1.23], I2=40%) between CD patients who had UST treatment preoperatively and those who had no UST treatment. There was no evidence of a difference in infectious complications (OR=1.15, p=0.35, 95%CI=[0.86-1.53], I2=2%). Additionally, there was no significant no evidence of difference between these group in terms of non-infectious complications and death. Specifically, there were no evidence of difference in overall complications, infection complications (including wound complications, sepsis, abscess and anastomotic leakage), and non-infection complications (ileus, readmission, and return to operation), compared with no biological therapy and anti-TNF-α agents. At the same time, no significant evidence of difference was discovered in the comparison of preoperative UST and VDZ therapy in terms of overall complications, infectious complications (sepsis and abscess), and non infectious complications (intestinal obstruction, readmission, and recovery surgery). Conclusion: In general, compared with other biological agents, preoperative use of UST in the treatment of CD patients is usually safe and does not increase surgical complications.
DOI: 10.6084/m9.figshare.23939280.v1
title: Supplementary Material for: Systematic review and meta-analysis: Association between preoperative ustekinumab and surgical complications in Crohn's disease patients

description: Introduction: The impact of ustekinumab (UST) therapy on surgical complications in patients with Crohn's disease (CD) remains controversial. The aim of this meta-analysis is to explore the link between these two. Methods: Databases (PubMed, Web of Science, Cochrane, and Springer Link) were searched until April 2022. Studies of CD patients who received UST and no UST prior to surgery (including no biological therapy, anti-TNF-α agent, and VDZ) were included. Primary outcomes included overall complications, infectious complications, and non-infectious complications. Results: Nine studies totaling 3,225 CD patients were enrolled; 332 patients received UST treatment. There was no evidence of difference in the overall complications (OR=0.84, p=0.37, 95%CI=[0.57-1.23], I2=40%) between CD patients who had UST treatment preoperatively and those who had no UST treatment. There was no evidence of a difference in infectious complications (OR=1.15, p=0.35, 95%CI=[0.86-1.53], I2=2%). Additionally, there was no significant no evidence of difference between these group in terms of non-infectious complications and death. Specifically, there were no evidence of difference in overall complications, infection complications (including wound complications, sepsis, abscess and anastomotic leakage), and non-infection complications (ileus, readmission, and return to operation), compared with no biological therapy and anti-TNF-α agents. At the same time, no significant evidence of difference was discovered in the comparison of preoperative UST and VDZ therapy in terms of overall complications, infectious complications (sepsis and abscess), and non infectious complications (intestinal obstruction, readmission, and recovery surgery). Conclusion: In general, compared with other biological agents, preoperative use of UST in the treatment of CD patients is usually safe and does not increase surgical complications.
DOI: 10.6084/m9.figshare.23939283
title: Supplementary Material for: Systematic review and meta-analysis: Association between preoperative ustekinumab and surgical complications in Crohn's disease patients

description: Introduction: The impact of ustekinumab (UST) therapy on surgical complications in patients with Crohn's disease (CD) remains controversial. The aim of this meta-analysis is to explore the link between these two. Methods: Databases (PubMed, Web of Science, Cochrane, and Springer Link) were searched until April 2022. Studies of CD patients who received UST and no UST prior to surgery (including no biological therapy, anti-TNF-α agent, and VDZ) were included. Primary outcomes included overall complications, infectious complications, and non-infectious complications. Results: Nine studies totaling 3,225 CD patients were enrolled; 332 patients received UST treatment. There was no evidence of difference in the overall complications (OR=0.84, p=0.37, 95%CI=[0.57-1.23], I2=40%) between CD patients who had UST treatment preoperatively and those who had no UST treatment. There was no evidence of a difference in infectious complications (OR=1.15, p=0.35, 95%CI=[0.86-1.53], I2=2%). Additionally, there was no significant no evidence of difference between these group in terms of non-infectious complications and death. Specifically, there were no evidence of difference in overall complications, infection complications (including wound complications, sepsis, abscess and anastomotic leakage), and non-infection complications (ileus, readmission, and return to operation), compared with no biological therapy and anti-TNF-α agents. At the same time, no significant evidence of difference was discovered in the comparison of preoperative UST and VDZ therapy in terms of overall complications, infectious complications (sepsis and abscess), and non infectious complications (intestinal obstruction, readmission, and recovery surgery). Conclusion: In general, compared with other biological agents, preoperative use of UST in the treatment of CD patients is usually safe and does not increase surgical complications.
DOI: 10.6084/m9.figshare.23939283.v1
title: Supplementary Material for: Systematic review and meta-analysis: Association between preoperative ustekinumab and surgical complications in Crohn's disease patients

description: Introduction: The impact of ustekinumab (UST) therapy on surgical complications in patients with Crohn's disease (CD) remains controversial. The aim of this meta-analysis is to explore the link between these two. Methods: Databases (PubMed, Web of Science, Cochrane, and Springer Link) were searched until April 2022. Studies of CD patients who received UST and no UST prior to surgery (including no biological therapy, anti-TNF-α agent, and VDZ) were included. Primary outcomes included overall complications, infectious complications, and non-infectious complications. Results: Nine studies totaling 3,225 CD patients were enrolled; 332 patients received UST treatment. There was no evidence of difference in the overall complications (OR=0.84, p=0.37, 95%CI=[0.57-1.23], I2=40%) between CD patients who had UST treatment preoperatively and those who had no UST treatment. There was no evidence of a difference in infectious complications (OR=1.15, p=0.35, 95%CI=[0.86-1.53], I2=2%). Additionally, there was no significant no evidence of difference between these group in terms of non-infectious complications and death. Specifically, there were no evidence of difference in overall complications, infection complications (including wound complications, sepsis, abscess and anastomotic leakage), and non-infection complications (ileus, readmission, and return to operation), compared with no biological therapy and anti-TNF-α agents. At the same time, no significant evidence of difference was discovered in the comparison of preoperative UST and VDZ therapy in terms of overall complications, infectious complications (sepsis and abscess), and non infectious complications (intestinal obstruction, readmission, and recovery surgery). Conclusion: In general, compared with other biological agents, preoperative use of UST in the treatment of CD patients is usually safe and does not increase surgical complications.
DOI: 10.34740/kaggle/dsv/6298988
title: Reef Ecological Assessment: Del Norte
DOI: 10.6084/m9.figshare.23939331
title: Supplementary Material for: Origin of residual tumor masses in BRCA1/2-driven ovarian carcinomas treated by neoadjuvant chemotherapy: selection of preexisting BRCA1/2-proficient tumor cells but not the gain of second ORF-restoring mutation

description: Introduction: Tubo-ovarian carcinomas (OCs) are highly sensitive to platinum-based neoadjuvant chemotherapy (NACT) but almost never demonstrate complete pathologic response. Methods: We analyzed paired primary and residual tumor tissues from 30 patients with hereditary BRCA1/2-driven OCs (BRCA1: 17; BRCA2: 13), who were treated by carboplatin/paclitaxel NACT (median number of cycles: 3, range 3-6). BRCA1/2 and TP53 genes were analyzed by the next-generation sequencing (NGS). The ratio between TP53 mutation-specific vs. wild-type reads was considered to monitor the proportion of tumor and non-tumor cells in the tissue sample, and the ratio between BRCA1/2 mutated and wild-type reads was used to estimate the presence of cells with the loss or retention of heterozygosity (LOH or ROH, respectively). Results: All 30 OCs had BRCA1/2 LOH in primary tumor and carried somatic TP53 mutation. Twenty-eight OCs had sufficient tumor cell cellularity in the post-NACT tissue to evaluate the ratio between mutated and wild-type BRCA1/2 alleles. Five (18%) out of 28 informative tumor pairs showed transition from LOH to ROH during NACT presumably affecting all or the vast majority of residual tumor cells. There were no signals of the emergence of a second open reading frame (ORF) restoring BRCA1/2 mutation. Conclusion: Chemonaive BRCA1/2-driven carcinomas may contain a fraction of tumor cells with preserved BRCA1/2 heterozygosity. NACT can cause a selection of pre-existing BRCA1/2-proficient tumor cells, without gaining secondary reversal BRCA1/2 mutations.
DOI: 10.6084/m9.figshare.23939331.v1
title: Supplementary Material for: Origin of residual tumor masses in BRCA1/2-driven ovarian carcinomas treated by neoadjuvant chemotherapy: selection of preexisting BRCA1/2-proficient tumor cells but not the gain of second ORF-restoring mutation

description: Introduction: Tubo-ovarian carcinomas (OCs) are highly sensitive to platinum-based neoadjuvant chemotherapy (NACT) but almost never demonstrate complete pathologic response. Methods: We analyzed paired primary and residual tumor tissues from 30 patients with hereditary BRCA1/2-driven OCs (BRCA1: 17; BRCA2: 13), who were treated by carboplatin/paclitaxel NACT (median number of cycles: 3, range 3-6). BRCA1/2 and TP53 genes were analyzed by the next-generation sequencing (NGS). The ratio between TP53 mutation-specific vs. wild-type reads was considered to monitor the proportion of tumor and non-tumor cells in the tissue sample, and the ratio between BRCA1/2 mutated and wild-type reads was used to estimate the presence of cells with the loss or retention of heterozygosity (LOH or ROH, respectively). Results: All 30 OCs had BRCA1/2 LOH in primary tumor and carried somatic TP53 mutation. Twenty-eight OCs had sufficient tumor cell cellularity in the post-NACT tissue to evaluate the ratio between mutated and wild-type BRCA1/2 alleles. Five (18%) out of 28 informative tumor pairs showed transition from LOH to ROH during NACT presumably affecting all or the vast majority of residual tumor cells. There were no signals of the emergence of a second open reading frame (ORF) restoring BRCA1/2 mutation. Conclusion: Chemonaive BRCA1/2-driven carcinomas may contain a fraction of tumor cells with preserved BRCA1/2 heterozygosity. NACT can cause a selection of pre-existing BRCA1/2-proficient tumor cells, without gaining secondary reversal BRCA1/2 mutations.
DOI: 10.21227/ndjb-x470
title: LEAVE-ONE-OUT ELECTROMYOGRAPHY (EMG) DATA SET OF 4 GESTURES PERFORMED WITH THE RIGHT HAND

description: A new design and implementation of a control system for an anthropomorphic robotic hand has been developed for the Bioinformatics and Autonomous Learning Laboratory (BALL) at ESPOL. Myoelectric signals were acquired using a bioelectric data acquisition board (CYTON BOARD) with six out of the available eight channels. These signals had an amplitude of 200 [uV] and were sampled at a frequency of 250 [Hz]. The data presented here extends the experiment conducted in the (ELECTROMYOGRAPHY (EMG) DATA SET OF 4 GESTURES PERFORMED WITH THE RIGHT HAND, ###), which was utilized for training, validation, and testing of the Multi-channel Biosignal Transformer (MuCBiT). For this purpose, five healthy subjects were recruited, including four females, with an average age of 28 years. All subjects were right-handed (with an Edinburgh Handedness Inventory (EHI) dexterity test score of 77.56), as measured by the Edinburgh Handedness Inventory (EHI) dexterity test (Oldfield RC, 1971).
DOI: 10.5281/zenodo.7040936
title: Direct strain correlations at the single-atom level in three-dimensional core-shell interface structures

description: The data and source codes for the paper [H.J., D.H.W., T.L., Y.K., C.J., J.L., H.B., A. J. P., W.T., C.O., P.E., Y.-L.L., S.R., S.W.H., and Y.Y., "Direct strain correlations at the single-atom level in three-dimensional core-shell interface structures", <em>Nat. Commun.</em> <strong>13</strong>, 5957 (2022)] are posted below. Nanomaterials with core-shell architectures are prominent examples of strain-engineered materials. The lattice mismatch between the core and shell materials can cause strong interface strain, which affects the surface structures. Therefore, surface functional properties such as catalytic activities can be designed by fine-tuning the misfit strain at the interface. To precisely control the core-shell effect, it is essential to understand how the surface and interface strains are related at the atomic scale. Here, we elucidate the surface-interface strain relations by determining the full 3D atomic structure of Pd@Pt core-shell nanoparticles at the single-atom level via atomic electron tomography. Full 3D displacement fields and strain profiles of core-shell nanoparticles were obtained, which revealed a direct correlation between the surface and interface strain. The strain distributions show a strong shape-dependent anisotropy, whose nature was further corroborated by molecular statics simulations. From the observed surface strains, the surface oxygen reduction reaction activities were predicted. These findings give a deep understanding of structure-property relationships in strain-engineerable core-shell systems, which can lead to direct control over the resulting catalytic properties.<br> <br> 1. Raw experimental tilt series images for Particle 1 and Particle 2 (Raw tilt series images.zip). 2. Denoised and aligned tilt series images for Particle 1 and Particle 2 (Finalized tilt series images.zip). 3. Finalized tilt angles for Particle 1 and Particle 2 (Finalized tilt angles.zip). 4. 3D tomographic reconstruction for Particle 1 and Particle 2 (Final reconstruction.zip). 5. Final atomic structure for Particle 1 and Particle 2 (Final atomic structure.zip). 6. Indices of surface Pd atoms for Particle 1 and Particle 2 (Indices of surface Pd.zip). 7. Source codes for the assignment of atomic coordinates, displacement/strain calculation and ORR activity calculation (Code_PdPt.zip). If you use any of the above data or source codes in your publications and/or presentations, our paper should be properly cited: H.J., D.H.W., T.L., Y.K., C.J., J.L., H.B., A. J. P., W.T., C.O., P.E., Y.-L.L., S.R., S.W.H., and Y.Y., "Direct strain correlations at the single-atom level in three-dimensional core-shell interface structures", <em>Nat. Commun.</em> <strong>13</strong>, 5957, (2022).<br> <br> If you have any questions regarding the above data or source codes, please contact Yongsoo Yang, Department of Physics, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Korea. Email: yongsoo.yang@kaist.ac.kr
DOI: 10.6084/m9.figshare.23937717.v1
title: List of Frameworks and Methodologies.xlsx

description: The full list of all the 103 frameworks and methodologies discussed in the context of software product management, together with their mention frequencies, and results of thematic analysis.
DOI: 10.25912/rdf_1650412444912
title: Supplementary data on Havre 2012 pink pumice
DOI: 10.6084/m9.figshare.23939394
title: Source data - Sang et al., 2023.

description: Source data of Sang et al., 2023.
DOI: 10.6084/m9.figshare.23939460
title: Supplementary Material for: Variation in ischemic stroke payments in the USA: a Medicare beneficiary study

description: Introduction: The growing cost of stroke care has created the need for outcome-oriented and cost-saving payment models. Identifying imbalances in the current reimbursement model is an essential step towards designing impactful value-based reimbursement strategies. This study describes the variation in reimbursement fees for ischemic stroke management across the United States. Methods: This Medicare Fee-For-Service claims study examines USA beneficiaries who suffered an ischemic stroke from 2021Q1 to 2022Q2 identified using the Medicare Severity Diagnosis-Related Groups (MS-DRGs). Demographic national and regional US data were extracted from the Census Bureau. The MS-DRG codes were grouped into four categories according to treatment modality and clinical complexity. Our primary outcome of interest was payments made across individual US states and US geographic regions, assessed by computing the mean incremental payment in cases of comparable complexity. Differences between states for each MS-DRG were statistically evaluated using a linear regression model of the logarithmic transformed payments. Results: 227,273 ischemic stroke cases were included in our analysis. Significant variations were observed among all DRG-groups defined by medical complexity, treatment modality, and states (p&lt;0.001). Differences in mean payment per case with the same MS-DRG vary by as high as 500% among individual states. Although higher payment rates were observed in MS-DRG codes with Major Comorbidities or Complexity, the variation was more expressive for codes without MCC. It was not possible to identify a standard mean incremental fee at a state level. At a regional level, the Northeast registered the highest fees, followed by the West, Midwest, and South, which correlates with poverty rates and median household income in the regions. Discussion/Conclusions: The payment variability observed across USA states suggests that the current reimbursement system needs to be aligned with stroke treatment costs. Future studies may go one step further to evaluate accurate stroke management costs to guide policymakers in introducing health policies that promote better care for stroke patients.
DOI: 10.6084/m9.figshare.23939460.v1
title: Supplementary Material for: Variation in ischemic stroke payments in the USA: a Medicare beneficiary study

description: Introduction: The growing cost of stroke care has created the need for outcome-oriented and cost-saving payment models. Identifying imbalances in the current reimbursement model is an essential step towards designing impactful value-based reimbursement strategies. This study describes the variation in reimbursement fees for ischemic stroke management across the United States. Methods: This Medicare Fee-For-Service claims study examines USA beneficiaries who suffered an ischemic stroke from 2021Q1 to 2022Q2 identified using the Medicare Severity Diagnosis-Related Groups (MS-DRGs). Demographic national and regional US data were extracted from the Census Bureau. The MS-DRG codes were grouped into four categories according to treatment modality and clinical complexity. Our primary outcome of interest was payments made across individual US states and US geographic regions, assessed by computing the mean incremental payment in cases of comparable complexity. Differences between states for each MS-DRG were statistically evaluated using a linear regression model of the logarithmic transformed payments. Results: 227,273 ischemic stroke cases were included in our analysis. Significant variations were observed among all DRG-groups defined by medical complexity, treatment modality, and states (p&lt;0.001). Differences in mean payment per case with the same MS-DRG vary by as high as 500% among individual states. Although higher payment rates were observed in MS-DRG codes with Major Comorbidities or Complexity, the variation was more expressive for codes without MCC. It was not possible to identify a standard mean incremental fee at a state level. At a regional level, the Northeast registered the highest fees, followed by the West, Midwest, and South, which correlates with poverty rates and median household income in the regions. Discussion/Conclusions: The payment variability observed across USA states suggests that the current reimbursement system needs to be aligned with stroke treatment costs. Future studies may go one step further to evaluate accurate stroke management costs to guide policymakers in introducing health policies that promote better care for stroke patients.
DOI: 10.6084/m9.figshare.23939469
title: Supplementary Material for: Variation in ischemic stroke payments in the USA: a Medicare beneficiary study

description: Introduction: The growing cost of stroke care has created the need for outcome-oriented and cost-saving payment models. Identifying imbalances in the current reimbursement model is an essential step towards designing impactful value-based reimbursement strategies. This study describes the variation in reimbursement fees for ischemic stroke management across the United States. Methods: This Medicare Fee-For-Service claims study examines USA beneficiaries who suffered an ischemic stroke from 2021Q1 to 2022Q2 identified using the Medicare Severity Diagnosis-Related Groups (MS-DRGs). Demographic national and regional US data were extracted from the Census Bureau. The MS-DRG codes were grouped into four categories according to treatment modality and clinical complexity. Our primary outcome of interest was payments made across individual US states and US geographic regions, assessed by computing the mean incremental payment in cases of comparable complexity. Differences between states for each MS-DRG were statistically evaluated using a linear regression model of the logarithmic transformed payments. Results: 227,273 ischemic stroke cases were included in our analysis. Significant variations were observed among all DRG-groups defined by medical complexity, treatment modality, and states (p&lt;0.001). Differences in mean payment per case with the same MS-DRG vary by as high as 500% among individual states. Although higher payment rates were observed in MS-DRG codes with Major Comorbidities or Complexity, the variation was more expressive for codes without MCC. It was not possible to identify a standard mean incremental fee at a state level. At a regional level, the Northeast registered the highest fees, followed by the West, Midwest, and South, which correlates with poverty rates and median household income in the regions. Discussion/Conclusions: The payment variability observed across USA states suggests that the current reimbursement system needs to be aligned with stroke treatment costs. Future studies may go one step further to evaluate accurate stroke management costs to guide policymakers in introducing health policies that promote better care for stroke patients.